Cook Research initiates RCT for Evero DCB in PAD treatment
The Evero drug-coated balloon is being evaluated for long-term safety and effectiveness against paclitaxel DCBs in PAD.
Asset / Drug
Drug and asset intelligence for Everolimus with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.